and other procedures to prevent the introduction, transmission, and spread of communicable diseases by HCT/P's.

- (b) Scope. (1) If you are an establishment that manufactures HCT/P's that are regulated solely under the authority of section 361 of the Public Health Service Act (the PHS Act), this part requires you to register and list your HCT/P's with the Food and Drug Administration's (FDA's) Center for Biologics Evaluation and Research and to comply with the other requirements contained in this part, whether or not the HCT/P enters into interstate commerce. Those HCT/P's that are regulated solely under the authority of section 361 of the PHS Act are described in § 1271.10.
- (2) If you are an establishment that manufactures HCT/P's that are regulated as drugs, devices and/or biological products under section 351 of the PHS Act and/or the Federal Food, Drug, and Cosmetic Act, §§ 207.20(f) and 807.20(d) of this chapter require you to register and list your HCT/P's following the procedures in subpart B of this part. Sections 210.1(c), 210.2, 211.1(b), and 820.1(a) of this chapter require you to comply with the donorsuitability procedures in subpart C of this part and the current good tissue practice procedures in subpart D of this part, in addition to all other applicable regulations.

§ 1271.3 How does FDA define important terms in this part?

The following definitions apply only to this part:

- (a) Autologous use means the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual from whom the cells or tissue were recovered.
- (b) Establishment means a place of business under one management, at one general physical location, that engages in the manufacture of human cells, tissues, and cellular and tissuebased products. "Establishment" includes:
- (1) Any individual, partnership, corporation, association, or other legal entity engaged in the manufacture of human cells, tissues, and cellular and tissue-based products; and

- (2) Facilities that engage in contract manufacturing services for a manufacturer of human cells, tissues, and cellular and tissue-based products.
- (c) Homologous use means the replacement or supplementation of a recipient's cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.
- (d)(1) Human cells, tissues, or cellular or tissue-based products (HCT/P's) means any human tissue derived from a human body and intended for transplantation into another human, as defined under § 1270.3(j). Examples of HCT/P's include, but are not limited to, bone, ligament, skin, and cornea.
- (e) Manufacture means, but is not limited to, any or all steps in the recovery, processing, storage, labeling, packaging, or distribution of any human cell or tissue, and the screening or testing of the cell or tissue donor.
 - (f) Minimal manipulation means:
- (1) For structural tissue, processing that does not alter the original relevant characteristics of the tissue relating to the tissue's utility for reconstruction, repair, or replacement; and
- (2) For cells or nonstructural tissues, processing that does not alter the relevant biological characteristics of cells or tissues.
- (g) *Transfer* means the placement of human reproductive cells or tissues into a human recipient.

EFFECTIVE DATE NOTE: At 66 FR 5466, Jan. 19, 2001, part 1271, consisting of §\$1271.1-1271.37, was added, effective Apr. 4, 2001, except for §1271.3(d)(2) which is effective Jan. 21, 2003. For the convenience of the user, the text of (d)(2) is set forth as follows:

§ 1271.3 How does FDA define important terms in this part?

(d) * * *

(2) Human cells, tissues, or cellular or tissue-based products (HCT/P's) means articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer into a human recipient. Examples of HCT/P's include, but are not limited to, bone, ligament, skin, dura mater, heart valve, cornea, hematopoietic stem cells derived from peripheral and cord blood, manipulated autologous chondrocytes, epithelial cells on

§ 1271.10

a synthetic matrix, and semen or other reproductive tissue. The following articles are not considered HCT/P's:

- (i) Vascularized human organs for transplantation;
- (ii) Whole blood or blood components or blood derivative products subject to listing under parts 607 and 207 of this chapter, respectively:
- (iii) Secreted or extracted human products, such as milk, collagen, and cell factors; except that semen is considered an HCT/P:
- (iv) Minimally manipulated bone marrow for homologous use and not combined with a drug or a device (except for a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the bone marrow);
- (v) Ancillary products used in the manufacture of HCT/P:
- (vi) Cells, tissues, and organs derived from animals other than humans; and

(vii) In vitro diagnostic products as defined in §809.3(a) of this chapter.

* * * * *

§ 1271.10 Are my HCT/P's regulated solely under section 361 of the PHS Act and the regulations in this part, and if so what must I do?

- (a) An HCT/P is regulated solely under section 361 of the PHS Act and the regulations in this part if it meets all of the following criteria:
- (1) The HCT/P is minimally manipulated:
- (2) The HCT/P is intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent;
- (3) The manufacture of the HCT/P does not involve the combination of the cell or tissue component with a drug or a device, except for a sterilizing, preserving, or storage agent, if the addition of the agent does not raise new clinical safety concerns with respect to the HCT/P; and
 - (4) Either:
- (i) The HCT/P does not have a systemic effect and is not dependent upon the metabolic activity of living cells for its primary function; or
- (ii) The HCT/P has a systemic effect or is dependent upon the metabolic activity of living cells for its primary function, and:
 - (a) Is for autologous use;
- (b) Is for allogeneic use in a first-degree or second-degree blood relative; or

- (c) Is for reproductive use.
- (b) If you are a domestic or foreign establishment that manufactures an HCT/P described in paragraph (a) of this section:
 - (1) You must register with FDA;
- (2) You must submit to FDA a list of each HCT/P manufactured; and
- (3) You must comply with the other requirements contained in this part.

§ 1271.15 Are there any exceptions from the requirements of this part?

- (a) You are not required to comply with the requirements of this part if you are an establishment that uses HCT/P's solely for nonclinical scientific or educational purposes.
- (b) You are not required to comply with the requirements of this part if you are an establishment that removes HCT/P's from an individual and implants such HCT/P's into the same individual during the same surgical procedure.
- (c) You are not required to comply with the requirements of this part if you are a carrier who accepts, receives, carries, or delivers HCT/P's in the usual course of business as a carrier.
- (d) You are not required to comply with the requirements of this part if you are an establishment that does not recover, screen, test, process, label, package, or distribute, but only receives or stores HCT/P's solely for implantation, transplantation, infusion, or transfer within your facility.
- (e) You are not required to comply with the requirements of this part if you are an establishment that only recovers reproductive cells or tissue and immediately transfers them into a sexually intimate partner of the cell or tissue donor.
- (f) You are not required to register or list your HCT/P's independently, but you must comply with all other applicable requirements in this part, if you are an individual under contract, agreement, or other arrangement with a registered establishment and engaged solely in recovering cells or tissues and sending the recovered cells or tissues to the registered establishment.